A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer
Authors:
- Hyuk-Chan KwonHKHyuk-Chan Kwon
- Bong-Gun SeoBSBong-Gun Seo
- Sung-Hyun KimSKSung-Hyun Kim
- Jae-Seok KimJKJae-Seok Kim
- Hyo-Jin KimHKHyo-Jin Kim
- 1 January 2007
- journal article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 46 (3) , 336-341
Abstract
To determine the activity and toxicities of a low dose leucovorin (ldLV) plus fluorouracil (5-FU) regimen, combined with oxaliplatin administered fortnightly (modified FOLFOX-4), as a first-line therapy for patients with advanced gastric cancer. Patients were treated with cycles of oxaliplatin 85 mg/m2 on day 1 plus LV 20 mg/m2, followed by 5-FU a 400 mg/m2 bolus and a 22 hour continuous infusion of 600 mg/m2 5-FU on days 1 - 2 every two week intervals. Forty-five patients were enrolled in this study. Forty-two patients were assessable for response. One of the 42 patients demonstrated complete response, and 20 partial responses, and overall response rate of 50%. The median time to progression and overall survival time were 7.7 months (95% CI: 3.6 - 11.9 months) and 11.2 months (95% CI: 9.1 - 13.3 months), respectively. Major hematologic toxicities included grade 1 - 2 anemia (39.7%), neutropenia (30.4%) and grade 3 - 4 neutropenia (10.9%). Twelve cycles were associated with neutropenic fever. The most common non-hematological toxicities were grade 2 nausea/vomiting (20%). There was no treatment related death. The modified FOLFOX-4 regimen was found to be a safe and effective first line therapy in advanced gastric cancer.Keywords
This publication has 21 references indexed in Scilit:
- Phase III Study of Fluorouracil, Leucovorin, and Levamisole in High-Risk Stage II and III Colon Cancer: Final Report of Intergroup 0089Journal of Clinical Oncology, 2005
- A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patientsBritish Journal of Cancer, 2005
- Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trialAnnals of Oncology, 2004
- Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancerBritish Journal of Cancer, 2004
- 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®)–cisplatin in advanced gastric carcinoma: a phase I–II trialAnnals of Oncology, 2004
- Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancerAnnals of Oncology, 2002
- 8. Aggressive LymphomasAnnals of Oncology, 2002
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Treatment of Advanced Gastric Cancer with DDP (Cisplatin), Adriamycin, and 5-FIuorouracil (DAF)Oncology, 1987
- Treatment of Advanced Measurable Gastric Carcinoma with 5-Fluorouracil, Adriamycin, and BCNUOncology, 1986